A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

NCT05346224 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms
HER2-positive Breast Cancer

Interventions

DRUG: HLX11
DRUG: EU-Perjeta®

Sponsor

Shanghai Henlius Biotech